What Happens to Refractory or Intolerant Chronic Myeloid Leukemia Patients without Access to Clinical Trials?

A great challenge to Chronic Myeloid Leukemia (CML) treatment is the management of refractory or intolerant patients to current TKI (imatinib, dasatinib and nilotinib). This special population usually can be included in clinical trials to have access to the new drugs.

Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Guilherme Bosi, Laura Fogliatto, Mariana Pinto, Tito Costa, Kamila Grokoski, Marco Abkalil, Camila Bender, Lucia Silla Source Type: research